FDA OKs Teclistamab for Relapsed/Refractory Multiple Myeloma FDA OKs Teclistamab for Relapsed/Refractory Multiple Myeloma

Teclistamab is now an option after progression on triple-class therapy; however, the FDA also issued a Boxed Warning for life-threatening or fatal cytokine release syndrome and neurologic toxicity.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news